RISK FACTORS FOR THROMBOTIC COMPLICATIONS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
(Abstract release date: 05/19/16)
EHA Library. Simonovic E. 06/09/16; 134936; PB2036
Dr. Evica Simonovic
Contributions
Contributions
Abstract
Abstract: PB2036
Type: Publication Only
Background
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. MPN are acquired prothrombogenic conditions. The mechanism of increased predisposition to thrombosis in myeloproliferative neoplasms is not clear enough. It is thought that the mechanisms that lead to thrombosis in MPN are the following: increased blood cell mass; abnormal platelet function and the phenomenon of spontaneous aggregation. The following factors have been associated with the incidence of thrombosis: the increased level of products formed in the activation of platelets (thromboxane, p-selectin); increased microparticle formation as the part of a membrane with various cell structures of platelet origin; JAK2V617F mutation. In MPN patients an increased activity of coagulation system occurs due to resistance to the anticoagulant function of thrombomodulin.
Aims
The aim of this study is to monitor potential risk factors for the development of thrombotic complications in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Methods
During the five-year period we monitored the occurrence of thrombotic complications in 139 patients of both sexes, aged between 30 and 87 years, being diagnosed with Ph-myeloproliferative neoplasm. Patients were classified into the following groups: 1. Group with the polycythemia vera (PV) (61); 2. Group with essential thrombocythemia (ET) (28); 3. Group with idiopathic myelofibrosis (IMF) (25); 4. Group with unclassified myeloproliferative neoplasm (MPNs) (25). The following possible risk factors were monitored: age, leukocyte count, platelet count, the presence of JAK2V617F mutation, cardiovascular risk factors (smoking, hypertension, diabetes mellitus, dyslipidemia). We used methods of clinical, laboratory, ultrasound and CT scans.
Results
The highest percentage of thrombotic complications (arterial and venous) was found in the group of patients with ET and MPNs (p <0,01), and then in the group with PV (p <0,05). In all three groups, the incidence of thrombotic complications in patients older than 60 years was higher (p<0,001). The leukocyte count ranged from 2,2-17,1 x 109/L and the platelet count ranged from 10,2 -1856,5 x 109/L. The highest leukocyte count was recorded in the group of patients with PV and MPNs (p <0,001) and the lowest in the group of patients with the IMF (p <0,01). The highest platelet count was found in the group of patients with ET, and the lowest in the group of patients IMF. Thrombotic complications in those groups were more frequent in percentage with patients with leukocytosis, but statistical significance was present only in the group with MPNs. No statistical significance was detected between the platelet count and thromboembolic complications in either group. Thrombotic complications were more frequent in JAK2V617F positive patients, but the statistical significance existed only in the group with PV. Considering cardiovascular risk factors only hypertension was significantly more common in the group with PV and MPNs. The largest number of patients with thrombotic complications had two or more cardiovascular risk factors (p <0,05).
Conclusion
The patients over 60 years of age, as well as the presence of two or more cardiovascular risk factors are the most important for the incidence of thrombosis. Leukocytosis and JAK2V617F may be considered as potential risk factors for thrombosis in patients with myeloproliferative neoplasms, particularly with PV, ET I MPNs. Further follow-up and a larger number of subjects are needed. The follow-up of patients with unclassified myeloproliferative neoplasms has particularly important, which showed a high prevalence of thrombotic complications, and with the aim of their further differentiation.
Session topic: E-poster
Keyword(s): Myeloproliferative disorder, Ph chromosome, Thromboembolic events
Type: Publication Only
Background
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. MPN are acquired prothrombogenic conditions. The mechanism of increased predisposition to thrombosis in myeloproliferative neoplasms is not clear enough. It is thought that the mechanisms that lead to thrombosis in MPN are the following: increased blood cell mass; abnormal platelet function and the phenomenon of spontaneous aggregation. The following factors have been associated with the incidence of thrombosis: the increased level of products formed in the activation of platelets (thromboxane, p-selectin); increased microparticle formation as the part of a membrane with various cell structures of platelet origin; JAK2V617F mutation. In MPN patients an increased activity of coagulation system occurs due to resistance to the anticoagulant function of thrombomodulin.
Aims
The aim of this study is to monitor potential risk factors for the development of thrombotic complications in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Methods
During the five-year period we monitored the occurrence of thrombotic complications in 139 patients of both sexes, aged between 30 and 87 years, being diagnosed with Ph-myeloproliferative neoplasm. Patients were classified into the following groups: 1. Group with the polycythemia vera (PV) (61); 2. Group with essential thrombocythemia (ET) (28); 3. Group with idiopathic myelofibrosis (IMF) (25); 4. Group with unclassified myeloproliferative neoplasm (MPNs) (25). The following possible risk factors were monitored: age, leukocyte count, platelet count, the presence of JAK2V617F mutation, cardiovascular risk factors (smoking, hypertension, diabetes mellitus, dyslipidemia). We used methods of clinical, laboratory, ultrasound and CT scans.
Results
The highest percentage of thrombotic complications (arterial and venous) was found in the group of patients with ET and MPNs (p <0,01), and then in the group with PV (p <0,05). In all three groups, the incidence of thrombotic complications in patients older than 60 years was higher (p<0,001). The leukocyte count ranged from 2,2-17,1 x 109/L and the platelet count ranged from 10,2 -1856,5 x 109/L. The highest leukocyte count was recorded in the group of patients with PV and MPNs (p <0,001) and the lowest in the group of patients with the IMF (p <0,01). The highest platelet count was found in the group of patients with ET, and the lowest in the group of patients IMF. Thrombotic complications in those groups were more frequent in percentage with patients with leukocytosis, but statistical significance was present only in the group with MPNs. No statistical significance was detected between the platelet count and thromboembolic complications in either group. Thrombotic complications were more frequent in JAK2V617F positive patients, but the statistical significance existed only in the group with PV. Considering cardiovascular risk factors only hypertension was significantly more common in the group with PV and MPNs. The largest number of patients with thrombotic complications had two or more cardiovascular risk factors (p <0,05).
Conclusion
The patients over 60 years of age, as well as the presence of two or more cardiovascular risk factors are the most important for the incidence of thrombosis. Leukocytosis and JAK2V617F may be considered as potential risk factors for thrombosis in patients with myeloproliferative neoplasms, particularly with PV, ET I MPNs. Further follow-up and a larger number of subjects are needed. The follow-up of patients with unclassified myeloproliferative neoplasms has particularly important, which showed a high prevalence of thrombotic complications, and with the aim of their further differentiation.
Session topic: E-poster
Keyword(s): Myeloproliferative disorder, Ph chromosome, Thromboembolic events
Abstract: PB2036
Type: Publication Only
Background
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. MPN are acquired prothrombogenic conditions. The mechanism of increased predisposition to thrombosis in myeloproliferative neoplasms is not clear enough. It is thought that the mechanisms that lead to thrombosis in MPN are the following: increased blood cell mass; abnormal platelet function and the phenomenon of spontaneous aggregation. The following factors have been associated with the incidence of thrombosis: the increased level of products formed in the activation of platelets (thromboxane, p-selectin); increased microparticle formation as the part of a membrane with various cell structures of platelet origin; JAK2V617F mutation. In MPN patients an increased activity of coagulation system occurs due to resistance to the anticoagulant function of thrombomodulin.
Aims
The aim of this study is to monitor potential risk factors for the development of thrombotic complications in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Methods
During the five-year period we monitored the occurrence of thrombotic complications in 139 patients of both sexes, aged between 30 and 87 years, being diagnosed with Ph-myeloproliferative neoplasm. Patients were classified into the following groups: 1. Group with the polycythemia vera (PV) (61); 2. Group with essential thrombocythemia (ET) (28); 3. Group with idiopathic myelofibrosis (IMF) (25); 4. Group with unclassified myeloproliferative neoplasm (MPNs) (25). The following possible risk factors were monitored: age, leukocyte count, platelet count, the presence of JAK2V617F mutation, cardiovascular risk factors (smoking, hypertension, diabetes mellitus, dyslipidemia). We used methods of clinical, laboratory, ultrasound and CT scans.
Results
The highest percentage of thrombotic complications (arterial and venous) was found in the group of patients with ET and MPNs (p <0,01), and then in the group with PV (p <0,05). In all three groups, the incidence of thrombotic complications in patients older than 60 years was higher (p<0,001). The leukocyte count ranged from 2,2-17,1 x 109/L and the platelet count ranged from 10,2 -1856,5 x 109/L. The highest leukocyte count was recorded in the group of patients with PV and MPNs (p <0,001) and the lowest in the group of patients with the IMF (p <0,01). The highest platelet count was found in the group of patients with ET, and the lowest in the group of patients IMF. Thrombotic complications in those groups were more frequent in percentage with patients with leukocytosis, but statistical significance was present only in the group with MPNs. No statistical significance was detected between the platelet count and thromboembolic complications in either group. Thrombotic complications were more frequent in JAK2V617F positive patients, but the statistical significance existed only in the group with PV. Considering cardiovascular risk factors only hypertension was significantly more common in the group with PV and MPNs. The largest number of patients with thrombotic complications had two or more cardiovascular risk factors (p <0,05).
Conclusion
The patients over 60 years of age, as well as the presence of two or more cardiovascular risk factors are the most important for the incidence of thrombosis. Leukocytosis and JAK2V617F may be considered as potential risk factors for thrombosis in patients with myeloproliferative neoplasms, particularly with PV, ET I MPNs. Further follow-up and a larger number of subjects are needed. The follow-up of patients with unclassified myeloproliferative neoplasms has particularly important, which showed a high prevalence of thrombotic complications, and with the aim of their further differentiation.
Session topic: E-poster
Keyword(s): Myeloproliferative disorder, Ph chromosome, Thromboembolic events
Type: Publication Only
Background
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. MPN are acquired prothrombogenic conditions. The mechanism of increased predisposition to thrombosis in myeloproliferative neoplasms is not clear enough. It is thought that the mechanisms that lead to thrombosis in MPN are the following: increased blood cell mass; abnormal platelet function and the phenomenon of spontaneous aggregation. The following factors have been associated with the incidence of thrombosis: the increased level of products formed in the activation of platelets (thromboxane, p-selectin); increased microparticle formation as the part of a membrane with various cell structures of platelet origin; JAK2V617F mutation. In MPN patients an increased activity of coagulation system occurs due to resistance to the anticoagulant function of thrombomodulin.
Aims
The aim of this study is to monitor potential risk factors for the development of thrombotic complications in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Methods
During the five-year period we monitored the occurrence of thrombotic complications in 139 patients of both sexes, aged between 30 and 87 years, being diagnosed with Ph-myeloproliferative neoplasm. Patients were classified into the following groups: 1. Group with the polycythemia vera (PV) (61); 2. Group with essential thrombocythemia (ET) (28); 3. Group with idiopathic myelofibrosis (IMF) (25); 4. Group with unclassified myeloproliferative neoplasm (MPNs) (25). The following possible risk factors were monitored: age, leukocyte count, platelet count, the presence of JAK2V617F mutation, cardiovascular risk factors (smoking, hypertension, diabetes mellitus, dyslipidemia). We used methods of clinical, laboratory, ultrasound and CT scans.
Results
The highest percentage of thrombotic complications (arterial and venous) was found in the group of patients with ET and MPNs (p <0,01), and then in the group with PV (p <0,05). In all three groups, the incidence of thrombotic complications in patients older than 60 years was higher (p<0,001). The leukocyte count ranged from 2,2-17,1 x 109/L and the platelet count ranged from 10,2 -1856,5 x 109/L. The highest leukocyte count was recorded in the group of patients with PV and MPNs (p <0,001) and the lowest in the group of patients with the IMF (p <0,01). The highest platelet count was found in the group of patients with ET, and the lowest in the group of patients IMF. Thrombotic complications in those groups were more frequent in percentage with patients with leukocytosis, but statistical significance was present only in the group with MPNs. No statistical significance was detected between the platelet count and thromboembolic complications in either group. Thrombotic complications were more frequent in JAK2V617F positive patients, but the statistical significance existed only in the group with PV. Considering cardiovascular risk factors only hypertension was significantly more common in the group with PV and MPNs. The largest number of patients with thrombotic complications had two or more cardiovascular risk factors (p <0,05).
Conclusion
The patients over 60 years of age, as well as the presence of two or more cardiovascular risk factors are the most important for the incidence of thrombosis. Leukocytosis and JAK2V617F may be considered as potential risk factors for thrombosis in patients with myeloproliferative neoplasms, particularly with PV, ET I MPNs. Further follow-up and a larger number of subjects are needed. The follow-up of patients with unclassified myeloproliferative neoplasms has particularly important, which showed a high prevalence of thrombotic complications, and with the aim of their further differentiation.
Session topic: E-poster
Keyword(s): Myeloproliferative disorder, Ph chromosome, Thromboembolic events
{{ help_message }}
{{filter}}